tradingkey.logo

Quanterix Corp

QTRX
查看詳細走勢圖
6.090USD
+0.210+3.57%
收盤 02/06, 16:00美東報價延遲15分鐘
284.30M總市值
虧損本益比TTM

Quanterix Corp

6.090
+0.210+3.57%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.57%

5天

-3.94%

1月

-6.45%

6月

+28.21%

今年開始到現在

-4.25%

1年

-25.00%

查看詳細走勢圖

TradingKey Quanterix Corp股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Quanterix Corp當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名89/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為7.50。中期看,股價處於上升通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Quanterix Corp評分

相關信息

行業排名
89 / 205
全市場排名
239 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Quanterix Corp亮點

亮點風險
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
業績高增長
公司營業收入穩步增長,連續3年增長30.23%
估值高估
公司最新PE估值-2.60,處於3年歷史高位
機構減倉
最新機構持股38.26M股,環比減少16.29%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉86.48K股

分析師目標

基於 4 分析師
持有
評級
7.500
目標均價
+18.67%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Quanterix Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Quanterix Corp簡介

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
公司代碼QTRX
公司Quanterix Corp
CEOToloue (Masoud)
網址https://www.quanterix.com/
KeyAI